CLGN — Collplant Biotechnologies Share Price
Last trade - 00:00- $20.85m
- $8.94m
- $0.52m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.55 | ||
| Price to Tang. Book | 1.56 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 40.48 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -109.6% | ||
| Return on Equity | -79.46% | ||
| Operating Margin | -3349.71% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 6.14 | 15.64 | 0.3 | 10.96 | 0.52 | 11.5 | 18 | -25.98% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
CollPlant Biotechnologies Ltd, formerly known as Collplant Holdings Ltd, is a company dealing in aesthetic medicine and regenerative medicine based in Israel. The company provides products and technologies for broadly understood regenerative medicine, including tissue regeneration and organ production. The technology is based on plants and is based on the production of collagen type I (rhCollagen).
Directors
- Roger Pomerantz NEC (64)
- Yehiel Tal CEO (68)
- Eran Rotem DCE (53)
- Ilana Belzer COO (61)
- Hadas Dreiher Horowitz VPR (44)
- Philippe Bensimon VPR (55)
- Nadav Orr VRD (63)
- Oded Shoseyov OTH (64)
- Gili Hart IND (46)
- Abraham Havron IND (73)
- Alisa Lask IND
- Elan Penn IND (69)
- Joseph Zarzewsky IND (59)
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- November 9th, 1981
- Public Since
- September 1st, 1993
- No. of Employees
- 57
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- NASDAQ Global Market
- Shares in Issue
- 11,454,512
- Address
- 4 Oppenheimer Street,, REHOVOT, 7670104
- Web
- https://www.collplant.com
- Phone
- +972 732325600
- Contact
- Eran Rotem
- Auditors
- Kost, Forer, Gabbay & Kasierer
Latest News for CLGN
Upcoming Events for CLGN
Q1 2025 Collplant Biotechnologies Ltd Earnings Release
Q2 2025 Collplant Biotechnologies Ltd Earnings Release
Q3 2025 Collplant Biotechnologies Ltd Earnings Release
Similar to CLGN
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
As of Today at 19:59 UTC, shares in Collplant Biotechnologies are trading at $1.82. This share price information is delayed by 15 minutes.
Shares in Collplant Biotechnologies last closed at $1.82 and the price had moved by -73.04% over the past 365 days. In terms of relative price strength the Collplant Biotechnologies share price has underperformed the S&P500 Index by -75.12% over the past year.
The overall consensus recommendation for Collplant Biotechnologies is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreCollplant Biotechnologies does not currently pay a dividend.
Collplant Biotechnologies does not currently pay a dividend.
Collplant Biotechnologies does not currently pay a dividend.
To buy shares in Collplant Biotechnologies you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $1.82, shares in Collplant Biotechnologies had a market capitalisation of $20.85m.
Here are the trading details for Collplant Biotechnologies:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: CLGN
Based on an overall assessment of its quality, value and momentum Collplant Biotechnologies is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
The analyst consensus target price for shares in Collplant Biotechnologies is $14.00. That is 669.23% above the last closing price of $1.82.
Analysts covering Collplant Biotechnologies currently have a consensus Earnings Per Share (EPS) forecast of -$0.11 for the next financial year.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Collplant Biotechnologies. Over the past six months, its share price has underperformed the S&P500 Index by -50.77%.
As of the last closing price of $1.82, shares in Collplant Biotechnologies were trading -52.8% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Collplant Biotechnologies PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.82.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Collplant Biotechnologies' management team is headed by:
- Roger Pomerantz - NEC
- Yehiel Tal - CEO
- Eran Rotem - DCE
- Ilana Belzer - COO
- Hadas Dreiher Horowitz - VPR
- Philippe Bensimon - VPR
- Nadav Orr - VRD
- Oded Shoseyov - OTH
- Gili Hart - IND
- Abraham Havron - IND
- Alisa Lask - IND
- Elan Penn - IND
- Joseph Zarzewsky - IND